ADORA2A and cancer: Targeting adenosine pathway, either blockade CD39 and CD73 with respective mAb to prevent the adenosine production or blockade the A2AR with inhibitors to interrupt adenosine-induced signal pathway, has been evaluated for cancer immunotherapy in pre-clinical studies and clinical trials.